Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Make a donation to fight colon cancer
In France, colon cancer is the second most common cancer among women and the third most common among men. When detected at an advanced or metastatic stage, colon cancer is very difficult to treat with current therapies and leaves patients with very little chance of recovery. Research is therefore the only hope.
-
3rd
Causes of death in France
-
65%
survival rate, an increase of 12 percentage points over 25 years
-
47,000
new cases per year in France
Through your donations, you can play an active role in driving innovation and accelerating research that directly benefits patients!
Understanding the Mechanisms by Which Colorectal Tumors Spread to the Liver and Peritoneum
This project aims to identify the mechanisms involved in the adhesion of tumor cells to one another and in their migration to other organs. The goal is to understand how colorectal cancer spreads in order to develop treatments that will block its progression.
Developing targeted therapies that will prevent the formation of metastases
The research team led by Dr. Fanny Jaulin, head of the “Collective Invasion” research team, recently discovered that tumor cells move in groups and form a protective shield, preventing any treatment from working effectively. Her research aims to develop treatments that will prevent tumor cells from clustering together and destroy the protective shield they form around themselves.
Developing Effective
Immunotherapies In half of all patients, colorectal cancer metastasizes to the liver. Surgery is the only way to remove these tumors, but it is feasible in only 15 to 20 percent of cases. The current goal is to increase the number of patients who are candidates for surgery by combining a low-dose injection of chemotherapy and immunotherapy directly into the tumor rather than administering them intravenously. The benefits for patients would include fewer side effects and a better chance of undergoing surgery.